[go: up one dir, main page]

DE69933460D1 - Mitogen- und stress-aktivierte proteinkinasen, die zwei kinase domänen enthalten, und deren verwendungen - Google Patents

Mitogen- und stress-aktivierte proteinkinasen, die zwei kinase domänen enthalten, und deren verwendungen

Info

Publication number
DE69933460D1
DE69933460D1 DE69933460T DE69933460T DE69933460D1 DE 69933460 D1 DE69933460 D1 DE 69933460D1 DE 69933460 T DE69933460 T DE 69933460T DE 69933460 T DE69933460 T DE 69933460T DE 69933460 D1 DE69933460 D1 DE 69933460D1
Authority
DE
Germany
Prior art keywords
mitogenic
stress
protein kinases
activated protein
kinase domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933460T
Other languages
English (en)
Other versions
DE69933460T2 (de
Inventor
Dario Alessi
Maria Deak
Philip Cohen
Matilde Caivano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813467.9A external-priority patent/GB9813467D0/en
Priority claimed from GBGB9817303.2A external-priority patent/GB9817303D0/en
Application filed by University of Dundee filed Critical University of Dundee
Application granted granted Critical
Publication of DE69933460D1 publication Critical patent/DE69933460D1/de
Publication of DE69933460T2 publication Critical patent/DE69933460T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69933460T 1998-06-24 1999-06-08 Mitogen- und stress-aktivierte proteinkinasen, die zwei kinase domänen enthalten, und deren verwendungen Expired - Lifetime DE69933460T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9813467 1998-06-24
GBGB9813467.9A GB9813467D0 (en) 1998-06-24 1998-06-24 Inhibition of protein kinases
GBGB9817303.2A GB9817303D0 (en) 1998-08-10 1998-08-10 Polypeptides polynucleotides and uses thereof
GB9817303 1998-08-10
PCT/GB1999/001660 WO1999067283A2 (en) 1998-06-24 1999-06-08 Two-kinase domain mitogen- and stress-activated protein kinases and uses thereof

Publications (2)

Publication Number Publication Date
DE69933460D1 true DE69933460D1 (de) 2006-11-16
DE69933460T2 DE69933460T2 (de) 2007-08-23

Family

ID=26313914

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933460T Expired - Lifetime DE69933460T2 (de) 1998-06-24 1999-06-08 Mitogen- und stress-aktivierte proteinkinasen, die zwei kinase domänen enthalten, und deren verwendungen

Country Status (6)

Country Link
US (1) US7122360B1 (de)
EP (1) EP1109918B1 (de)
JP (1) JP4588215B2 (de)
AU (1) AU4273099A (de)
DE (1) DE69933460T2 (de)
WO (1) WO1999067283A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224321A2 (de) * 1999-10-13 2002-07-24 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Ein verfahren zum auffinden von substanzen die auf msk1 einwirken
AU2007202447B2 (en) * 2000-10-25 2010-03-11 Aventis Pharma Sa Net as regulator of angiogenic expression
EP1202065A1 (de) * 2000-10-25 2002-05-02 Aventis Pharma S.A. NET, ein Transkriptionsfaktor aus der "TCF"-Familie, als Regulator von angiogener Expression
WO2003008577A1 (fr) 2001-07-16 2003-01-30 Fuyuki Ishikawa Nouvelles cellules transformees, methode de criblage d'agent anti-vieillissement et agents anti-vieillissement
DE10220480C1 (de) * 2002-05-07 2003-09-11 Ulf R Rapp Verfahren zur Herstellung von Zellen mit erhöhtem Entwicklungspotential
EP1708697A4 (de) 2004-01-30 2007-11-28 Smithkline Beecham Corp Chemische verbindungen
US8653086B2 (en) 2008-10-21 2014-02-18 Oregon Health & Science University Naphthamides as anticancer agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643758A (en) * 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO1993019752A1 (en) 1992-04-07 1993-10-14 Dana-Farber Cancer Institute, Inc. Inhibition of p70 s6 kinase
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
EP0833664A1 (de) * 1995-06-12 1998-04-08 G.D. SEARLE & CO. Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen
WO1997044467A1 (en) 1996-05-20 1997-11-27 Signal Pharmaceuticals, Inc. MITOGEN-ACTIVATED PROTEIN KINASE p38-2 AND METHODS OF USE THEREFOR
GB9615498D0 (en) 1996-07-24 1996-09-04 Ciba Geigy Ag Kinase

Also Published As

Publication number Publication date
DE69933460T2 (de) 2007-08-23
WO1999067283A2 (en) 1999-12-29
EP1109918A2 (de) 2001-06-27
WO1999067283A3 (en) 2001-04-12
AU4273099A (en) 2000-01-10
EP1109918B1 (de) 2006-10-04
WO1999067283A8 (en) 2000-05-04
JP2002518036A (ja) 2002-06-25
JP4588215B2 (ja) 2010-11-24
US7122360B1 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
DE69435267D1 (de) Proteinkinase C Inhibitoren
HUS1700048I1 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
HUP0103617A2 (hu) Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
PL346700A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
DE69913364D1 (en) Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
NO20006090L (no) Pyrrolo(2,3d)pyrimidin sammensetninger og anvendelse herav
DK0776895T3 (da) Proteinkinase C inhibitor
DE69920390D1 (de) Mram mit geteilten wort-und bitleitungen
FI971225L (fi) Pyrrolo(2,3-d)pyrimidiinit ja niiden käyttö
CA2322311A1 (en) Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
NO20006454L (no) Pyrrolo(2,3-d)pyrimidinforbindelser
IT1313834B1 (it) Autoveicolo con dispositivo di riconoscimento dell'intenzione dicambio
ATE534457T1 (de) Fraktalstruktur zum mischen von mindestens zwei fluiden
DE59808346D1 (de) Behälter mit zwei Aufnahmeräumen
NL1009107A1 (nl) Gelatine-uitspreidende doos met meervoudige, aanpasbare poortklep en meerlagig zacht gel.
DE69929926D1 (de) Kältespeichermaterial und dasselbe verwendende Kältemaschine mit Kältespeicherung
DE69700330D1 (de) Dicke werkstuecke aus al-zn-mg-cu legierung mit verbesserten eigenschaften
EP1112354A4 (de) Neuartige proteinkinase moleküle sowie deren verwendungen
DE59915065D1 (de) Halbleiterbauelement mit mehreren halbleiterchips
DE69917327D1 (de) 3,3-biarylpiperidin- und 3,3-biarylmorpholinderivate
DE69933460D1 (de) Mitogen- und stress-aktivierte proteinkinasen, die zwei kinase domänen enthalten, und deren verwendungen
ZA200307306B (en) Indolines, substituted in portion 6, and their use as kinase inhibitors.
TR199500758A2 (tr) Lökotriarilmetanlarin hidrokarbonlarin isaretlenmesinde kullanilmasi.
DE69503025D1 (de) Füllminenstift mit zwei Spannbacken
DE69728726D1 (de) Blockierungsfeder mit Fluidum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: STROHSCHAENK UND KOLLEGEN, 85521 OTTOBRUNN